동물용 백신 시장 : 제품 유형, 동물 유형, 투여 경로, 가수, 보관 조건, 질환 유형, 유통 채널별 예측(2026-2032년)

The Veterinary Vaccines Market is projected to grow by USD 24.15 billion at a CAGR of 6.99% by 2032.

Veterinary Vaccines Executive Summary

Veterinary vaccines are central to animal health, food security, zoonotic disease prevention, and sustainable livestock productivity. They help protect companion animals, poultry, swine, cattle, aquaculture species, and other livestock from viral, bacterial, and parasitic diseases while reducing the need for therapeutic antimicrobials. Demand for effective animal vaccines is being shaped by intensified livestock production, expanding pet ownership, cross-border animal trade, climate-driven disease range shifts, and heightened awareness of One Health principles linking animal, human, and environmental health.

The veterinary vaccines landscape includes live attenuated, inactivated, recombinant, subunit, toxoid, conjugate, DNA, RNA, and vector-based platforms. Core use cases span preventive immunization against diseases such as rabies, foot-and-mouth disease, avian influenza, Newcastle disease, classical swine fever, porcine reproductive and respiratory syndrome, bovine respiratory disease, brucellosis, and leptospirosis. Regulatory oversight, cold-chain reliability, strain matching, pharmacovigilance, and field-level vaccination compliance remain decisive factors in vaccine effectiveness. As animal disease surveillance becomes more integrated with digital reporting and genomic epidemiology, veterinary vaccination strategies are moving from reactive outbreak response toward risk-based, data-informed prevention.

Transformative Shifts in the Veterinary Vaccines Landscape

The veterinary vaccines industry is undergoing transformative change as animal health systems adapt to evolving disease ecology, stricter biosecurity expectations, and the global push to reduce antimicrobial use. Public authorities and producers increasingly recognize vaccination as a frontline tool for preventing production losses, limiting disease transmission, and supporting responsible antibiotic stewardship. This is particularly relevant in intensive poultry, swine, and cattle systems where infectious disease outbreaks can rapidly disrupt supply chains and trade flows.

Innovation is shifting vaccine development toward recombinant antigen design, viral vectors, marker vaccines compatible with differentiating infected from vaccinated animals, and next-generation nucleic acid platforms. These approaches can support faster strain updates and more targeted immune responses than many traditional platforms, although practical adoption depends on stability, cost, regulatory acceptance, and administration feasibility. At the same time, oral, intranasal, in ovo, and mass-application delivery methods are gaining importance because ease of administration influences coverage rates in large herds and flocks.

Another major shift is the growing connection between vaccination, surveillance, and traceability. Disease reporting platforms, farm management systems, and laboratory networks are enabling more timely identification of emerging threats. Governments and industry stakeholders are also strengthening preparedness for transboundary animal diseases, including avian influenza, African swine fever, foot-and-mouth disease, and rabies, where coordinated vaccination policy, diagnostics, movement control, and biosecurity must work together.

Cumulative Impact of Artificial Intelligence on Veterinary Vaccines

Artificial intelligence is increasingly influencing veterinary vaccines across discovery, development, manufacturing, distribution, and post-vaccination monitoring. In research and development, AI-supported immunoinformatics can help screen pathogen genomes, identify candidate antigens, model protein structures, and prioritize epitopes with potential to trigger protective immune responses. These methods do not replace laboratory validation or animal challenge studies, but they can improve early-stage decision-making and reduce time spent evaluating low-probability candidates.

In disease surveillance, AI models can analyze veterinary laboratory results, animal movement data, climate variables, syndromic reports, and production anomalies to detect outbreak signals earlier. For vaccine programs, these tools can support risk-based targeting by identifying areas or production systems with elevated exposure risk. In manufacturing and quality systems, machine learning can assist process monitoring, deviation detection, batch consistency analysis, and predictive maintenance, all of which are important for biologics where reliability and compliance are critical.

AI also strengthens field implementation. Digital vaccination records, image-based animal identification, automated reminders, and analytics dashboards can improve adherence to immunization schedules in livestock and companion animals. However, responsible adoption requires high-quality datasets, transparent validation, cybersecurity safeguards, and clear governance around data ownership. The cumulative impact of AI is therefore best understood as an enabling layer that supports faster insight, better targeting, and improved vaccine program performance rather than as a substitute for veterinary expertise and regulatory evidence.

Key Regional Insights for Veterinary Vaccines

Asia-Pacific is a critical region for veterinary vaccines because of its large livestock populations, dense poultry and swine production systems, expanding aquaculture activity, and recurring exposure to transboundary animal diseases. Countries across the region have strengthened vaccination and surveillance for avian influenza, foot-and-mouth disease, classical swine fever, rabies, and other priority diseases, while companion animal vaccination is rising alongside urban pet ownership. The region's diversity creates uneven adoption patterns, with advanced cold-chain and regulatory systems in some markets and access challenges in rural or smallholder settings in others.

North America is characterized by established veterinary care infrastructure, strong companion animal vaccination compliance, commercial livestock health programs, and integrated disease surveillance. Rabies control, bovine respiratory disease prevention, swine and poultry vaccination protocols, and preparedness for foreign animal diseases remain important priorities. Veterinary vaccines are closely linked to food safety, biosecurity, and antimicrobial stewardship initiatives across production systems.

Latin America's veterinary vaccine demand is shaped by cattle production, poultry and swine expansion, and the region's long-standing focus on foot-and-mouth disease control. Brazil and Mexico play important roles in regional animal protein supply chains, while rabies, brucellosis, leptospirosis, and clostridial diseases remain relevant targets. Vaccination policies often interact with export requirements, official disease status, and farm-level biosecurity investments.

Europe maintains rigorous animal health regulation, pharmacovigilance expectations, and coordinated surveillance for zoonotic and transboundary diseases. The region emphasizes antimicrobial reduction, animal welfare, and traceable livestock production, supporting preventive vaccination where epidemiologically justified. Avian influenza preparedness, bluetongue control, rabies prevention in at-risk areas, and livestock disease management are prominent themes.

The Middle East faces veterinary vaccine needs linked to ruminant health, poultry production, camel health, and cross-border animal movement. Foot-and-mouth disease, peste des petits ruminants, brucellosis, rabies, and poultry diseases are important concerns, and vaccination programs are often aligned with import controls, food security strategies, and regional disease surveillance. Climate stress and animal trade routes add complexity to prevention planning.

Africa has substantial unmet need for veterinary vaccination due to the burden of livestock diseases affecting livelihoods, food security, and public health. Priority areas include peste des petits ruminants, contagious bovine pleuropneumonia, foot-and-mouth disease, Newcastle disease, rabies, brucellosis, and lumpy skin disease. Progress depends on vaccine availability, affordability, cold-chain capacity, community-level delivery, and sustained public-private coordination, especially in pastoral and smallholder production systems.

Key Group Insights for Veterinary Vaccines

ASEAN veterinary vaccine priorities are influenced by dense animal production, smallholder farming, regional animal movement, and persistent risks from avian influenza, foot-and-mouth disease, classical swine fever, rabies, and emerging zoonoses. The group's animal health agenda increasingly links vaccination with surveillance, laboratory capacity, and food security. Harmonization of standards and cross-border coordination remain important because disease threats often extend beyond national boundaries.

The GCC's veterinary vaccine needs reflect food security planning, intensive poultry development, ruminant health, camel populations, and reliance on animal imports. Vaccination strategies in the group are closely tied to border inspection, quarantine, disease monitoring, and prevention of foot-and-mouth disease, peste des petits ruminants, brucellosis, rabies, and poultry pathogens. Hot climates and logistics requirements make cold-chain performance and field administration planning especially important.

The European Union applies a highly structured regulatory and surveillance framework that supports evidence-based vaccine authorization, monitoring, and use. Animal vaccination strategies are shaped by disease status rules, movement controls, antimicrobial reduction policies, and coordinated response planning for avian influenza, bluetongue, rabies, and other regulated diseases. The group's emphasis on traceability and pharmacovigilance supports high confidence in vaccine quality and safety.

BRICS countries represent diverse veterinary vaccine conditions, ranging from large commercial livestock sectors to extensive smallholder systems. China, India, Brazil, Russia, and South Africa face significant animal health priorities involving foot-and-mouth disease, avian influenza, swine diseases, brucellosis, rabies, and endemic livestock infections. Their collective importance lies in large animal populations, animal protein production, domestic biologics capacity, and the need for scalable immunization programs.

G7 countries generally have mature animal health governance, advanced veterinary services, strong companion animal vaccination practices, and established biologics regulation. Their priorities include biosecurity, pandemic preparedness for zoonotic and animal-origin threats, antimicrobial stewardship, and resilient food supply chains. Veterinary vaccines in these countries are increasingly integrated with diagnostics, digital records, and risk-based surveillance.

NATO member countries overlap substantially with high-income veterinary health systems but also include varied livestock structures and regional disease risks. Veterinary vaccine relevance within this group extends beyond agriculture to biosecurity, food supply resilience, working animals, and preparedness for deliberate or accidental biological threats affecting animals. Coordinated surveillance and emergency response capacity strengthen vaccination planning for high-consequence animal diseases.

Key Country Insights for Veterinary Vaccines

The United States has a highly developed veterinary vaccine environment supported by commercial livestock production, companion animal healthcare, federal and state disease surveillance, and strong biosecurity programs. Priorities include rabies prevention, poultry vaccination, swine disease management, cattle respiratory and reproductive disease control, and preparedness for foreign animal diseases. Canada emphasizes livestock health, companion animal immunization, antimicrobial stewardship, and surveillance for diseases affecting cattle, swine, poultry, wildlife, and trade. Mexico's veterinary vaccine priorities include rabies control, cattle health, poultry and swine disease prevention, and vaccination programs linked to food production and regional trade.

Brazil is a major animal protein producer where vaccination is closely tied to cattle, poultry, swine, and companion animal health, with foot-and-mouth disease policy, rabies prevention, clostridial disease control, and poultry biosecurity remaining important. The United Kingdom maintains strong companion animal vaccination practices, livestock disease monitoring, and biosecurity planning, with attention to avian influenza, bovine diseases, sheep health, and regulatory oversight. Germany's veterinary vaccine landscape is shaped by advanced animal health infrastructure, intensive livestock systems, companion animal care, and EU-aligned regulation. France combines robust livestock vaccination practices, poultry and ruminant health programs, and strong surveillance for zoonotic and regulated diseases.

Russia faces significant veterinary vaccine needs across large cattle, poultry, swine, and companion animal populations, with attention to avian influenza, rabies, brucellosis, foot-and-mouth disease, and other endemic or transboundary threats. Italy's priorities include companion animal vaccination, cattle and small ruminant health, poultry disease prevention, and regional surveillance for vector-borne and zoonotic infections. Spain has notable livestock and companion animal vaccine use, with swine, poultry, ruminant, and rabies-related prevention supported by veterinary services and EU regulatory standards.

China has one of the world's largest livestock populations, making veterinary vaccines essential for poultry, swine, cattle, sheep, aquaculture, and companion animals. National attention to avian influenza, foot-and-mouth disease, rabies, swine diseases, and food security has strengthened vaccine development and disease control capacity. India's priorities include foot-and-mouth disease, brucellosis, peste des petits ruminants, classical swine fever, rabies, and poultry diseases, with vaccination playing a major role in supporting smallholders, dairy systems, and public health.

Japan maintains a controlled and highly regulated veterinary vaccine environment with strong companion animal care, livestock disease surveillance, and emphasis on biosecurity. Australia's animal health system benefits from geographic biosecurity, structured surveillance, and vaccination programs for livestock and companion animals, with continued focus on preparedness for exotic disease incursions and endemic livestock conditions. South Korea emphasizes high-density livestock health, companion animal vaccination, and preparedness for avian influenza, foot-and-mouth disease, African swine fever control measures, and other high-impact animal disease risks.

Actionable Recommendations for Veterinary Vaccine Leaders

Industry vendors should prioritize vaccine portfolios that align with high-burden endemic diseases, emerging zoonotic risks, and production-system-specific needs. Investment in recombinant, vector-based, marker, mucosal, and thermostable vaccine technologies can improve differentiation, field utility, and outbreak readiness. At the same time, traditional vaccine platforms remain important where they deliver proven protection, established regulatory pathways, and cost-effective deployment.

Strengthening surveillance partnerships is essential. Vaccine developers, animal health authorities, laboratories, veterinarians, and producers should integrate diagnostic data, pathogen sequencing, field effectiveness monitoring, and adverse event reporting to refine strain selection and vaccination protocols. Cold-chain resilience, last-mile distribution, and training for vaccinators should receive the same strategic attention as product innovation, particularly in rural, smallholder, and tropical settings.

Vendors should also embed antimicrobial stewardship and One Health value propositions into veterinary vaccine strategies. Demonstrating reductions in disease incidence, mortality, treatment frequency, and outbreak-related disruption can support adoption by producers and policymakers. Digital vaccination records, AI-enabled risk analytics, and farm-level decision tools can improve compliance and traceability when designed with practical workflows and data governance in mind.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available and institutionally recognized sources relevant to veterinary vaccines, animal health, zoonotic disease prevention, and biologics regulation. The methodology emphasizes evidence from veterinary public health agencies, animal health organizations, regulatory authorities, peer-reviewed scientific literature, national disease control programs, and recognized epidemiological surveillance resources.

The analysis focuses on qualitative, data-backed indicators such as disease burden, vaccination policy priorities, regulatory frameworks, livestock and companion animal health dynamics, biosecurity needs, antimicrobial stewardship relevance, and regional animal production characteristics. Information is synthesized to identify strategic themes across technology platforms, disease targets, delivery systems, regional conditions, and adoption enablers. No market sizing, market estimation, market share, or forecasting assumptions are applied.

Quality control involves cross-checking disease and vaccination themes across multiple credible references, prioritizing recent and authoritative materials, and avoiding unsupported claims. Regional, group, and country insights are presented as narrative interpretations of verified animal health trends rather than numerical projections.

Conclusion

Veterinary vaccines are becoming increasingly important as animal health systems confront infectious disease pressure, zoonotic risk, food security demands, antimicrobial resistance concerns, and changing production models. The sector is advancing through a combination of proven vaccine platforms, next-generation biologics, digital surveillance, AI-enabled analytics, and stronger policy alignment around One Health.

Future competitiveness will depend on the ability to deliver safe, effective, accessible, and field-adapted vaccines across diverse animal populations and geographies. Stakeholders that combine scientific innovation with surveillance integration, regulatory readiness, cold-chain execution, and clear evidence of farm-level value will be best positioned to support resilient animal health systems and sustainable protein supply chains.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Vaccines Market, by Product Type

• 7.1. Inactivated Vaccines
• 7.2. Live Attenuated Vaccines
• 7.3. Subunit & Recombinant Vaccines
• 7.4. Viral Vector Vaccines

8. Veterinary Vaccines Market, by Animal Type

• 8.1. Companion Animals
  • 8.1.1. Cats
  • 8.1.2. Dogs
• 8.2. Livestock Animals
  • 8.2.1. Cattle
  • 8.2.2. Poultry
  • 8.2.3. Sheep
  • 8.2.4. Swine

9. Veterinary Vaccines Market, by Route Of Administration

• 9.1. Oral
• 9.2. Parenteral
• 9.3. Topical

10. Veterinary Vaccines Market, by Valency

• 10.1. Monovalent
• 10.2. Multivalent

11. Veterinary Vaccines Market, by Storage Requirement

• 11.1. Refrigerated
• 11.2. Frozen
• 11.3. Thermostable

12. Veterinary Vaccines Market, by Disease Type

• 12.1. Bacterial Infections
  • 12.1.1. Clostridial
  • 12.1.2. E. Coli
  • 12.1.3. Leptospirosis
  • 12.1.4. Pasteurella
• 12.2. Fungal Infections
• 12.3. Parasitic Infections
  • 12.3.1. Ectoparasites
  • 12.3.2. Endoparasites
• 12.4. Viral Infections
  • 12.4.1. Avian Influenza Virus
  • 12.4.2. Bovine Viral Diarrhea Virus (BVDV)
  • 12.4.3. Foot-and-Mouth Disease Virus (FMDV)
  • 12.4.4. Newcastle Disease Virus
  • 12.4.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
  • 12.4.6. Rabies Virus

13. Veterinary Vaccines Market, by Distribution Channel

• 13.1. Online Pharmacies
• 13.2. Retail Pharmacies
• 13.3. Veterinary Clinics

14. Veterinary Vaccines Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Veterinary Vaccines Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Veterinary Vaccines Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Aptimmune Biologics, Inc.
• 18.2. Arko Corp.
• 18.3. Bimeda Biologicals Inc
• 18.4. Biogenesis Bago S.A.
• 18.5. Boehringer Ingelheim International GmbH
• 18.6. Brilliant Bio Pharma Private Limited
• 18.7. Ceva Sante Animale
• 18.8. Dechra Pharmaceuticals PLC
• 18.9. Elanco Animal Health Incorporated
• 18.10. Endovac Animal Health
• 18.11. Hester Biosciences Limited
• 18.12. Hipra S.A.
• 18.13. Huvepharma, Inc.
• 18.14. Indian Immunologicals Ltd.
• 18.15. Jinyu Bio-technology Co., Ltd.
• 18.16. Kemin Industries, Inc.
• 18.17. Merck & Co., Inc.
• 18.18. Neogen Corporation
• 18.19. Pfizer, Inc.
• 18.20. Phibro Animal Health Corporation
• 18.21. SAN Group Biotech Germany GmbH
• 18.22. Seppic by Air Liquide Healthcare
• 18.23. SK Bioscience
• 18.24. Vaxine Pty Ltd.
• 18.25. Vaxxinova
• 18.26. Virbac S.A.
• 18.27. Zoetis Inc.